%0 Journal Article
%T Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased in vivo anti-tumor efficacy
%A Chengchao Shou
%A Chuanke Zhao
%A Guo An
%A Hua Zhu
%A Huifang Tian
%A Junnan Feng
%A Like Qu
%A Lixin Wang
%A Zhi Yang
%J Theranostics
%D 2018
%I Ivyspring International Publisher
%R 10.7150/thno.22069
%X Angiogenesis plays a critical role in tumor aggressiveness, and a lot of anti-angiogenic agents have been used in clinical therapy. The therapeutic efficacy of peptides are generally restricted by the short in vivo life-time, thus, we were interested in developing a novel albumin-based and maleimidopropionic acid-conjugated peptide to prolong the half-life and improve the anti-tumor effect.
%K F56
%K MPA
%K albumin conjugate
%K anti-tumor
%K VEGFR1
%U http://www.thno.org/v08p2094.htm